Evidence map›Paper›PMID 41937137›Full record

Trial reportBMC medicine2026

Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial.

Maoying Guan, Wencheng Zhao, Wengang Zhang, Xuyang Chen, Runze Huang, Xinyue Liu, Yujie Li, Hao Wang, Lishu Zhao, Kandi Xu and 6 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04698941 (Clinical Study of Albumin Paclitaxel With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04698941 phase2unknown statusnot on this map

Clinical Study of Albumin Paclitaxel With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy

TypeinterventionalSponsorShanghai Pulmonary Hospital, Shanghai, ChinaRan2021 to 2022Enrolled40ConditionsSmall Cell Lung CancerArmsAlbumin Paclitaxel, Simvastatin
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maoying Guan *Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Wencheng Zhao *Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Wengang Zhang *Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Xuyang Chen *Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Runze HuangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Xinyue LiuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Yujie LiDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Hao WangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Lishu ZhaoDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Kandi XuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Li YeDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Zhimin ChenDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Yujin LiuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Qianqian ZhangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Hongbin JiWestlake University School of Medicine, Hangzhou, 310030, Zhejiang, China. jihongbin@westlake.edu.cn.ORCID 0000-0003-0891-6390
Yayi HeDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. yayi.he@tongji.edu.cn.ORCID 0000-0002-2820-9119

Funding

2021 Science and Technology Think Tank Youth Talent Plan of China Association for Science and Technology, National Key Research and Development Program of China 2021YFF1201200a grant of National Key Research and Development Program of China 2022YFF0705300National Natural Science Foundation of China 52272281Shanghai Municipal Health Commission Scientific Research Project 20244Y0111Shanghai Municipal Science and Technology Major Project 2021SHZDZX0100the Fundamental Research Funds for the Central Universities, Shanghai Municipal Health Commission Health Industry Clinical Research Project, Clinical Research Project of Shanghai Pulmonary Hospital FKLY20010Young Talents in Shanghai 2019 QNBJ
6 · The paper itself

Abstract

backgroundSmall-cell lung cancer (SCLC) responds to first-line therapy, but most patients rapidly develop resistance. This study aimed to investigate the efficacy and safety of nab-paclitaxel combined with simvastatin as second-line treatment for SCLC patients.

methodsIn this phase II randomized trial, patients received nab-paclitaxel alone or in combination with simvastatin. The primary endpoint was disease control rate (DCR); secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.

resultsDCR was higher for the nab-paclitaxel plus simvastatin group than in the nab-paclitaxel group (92.9% vs. 44.4%, P = 0.005). ORR (50.0% vs. 11.1%, P = 0.017) and median PFS (113 vs. 62 days; HR = 0.42, 95% CI = 0.19-0.92; P = 0.029) were also improved. No significant difference in OS was observed. Treatment-related toxicities were manageable in both groups.

conclusionsIn this phase II randomized study, nab-paclitaxel plus simvastatin was associated with improved DCR, ORR, and PFS, with manageable toxicity, as second-line treatment for patients with small-cell lung cancer.

trial registrationClinicalTrials.gov NCT04698941.

Indexed as

Albumin-Bound PaclitaxelAlbuminsAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsPaclitaxelSimvastatinSmall Cell Lung CarcinomaAdultAgedFemaleHumansMaleMiddle AgedTreatment Outcome130-nm albumin-bound paclitaxelAlbumin-Bound PaclitaxelAlbuminsPaclitaxelSimvastatinChemotherapy resistanceGGPS1Nab-paclitaxelSCLCSecond-line treatmentSimvastatin

Identifiers

PMID41937137
PMCPMC13343679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.